Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Income towards Common Stockholders: 2020-2025

Historic Net Income towards Common Stockholders for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$10.9 million.

  • Insight Molecular Diagnostics' Net Income towards Common Stockholders rose 19.56% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.9 million, marking a year-over-year decrease of 39.68%. This contributed to the annual value of -$61.0 million for FY2024, which is 1986.16% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Net Income towards Common Stockholders stood at -$10.9 million for Q3 2025, which was down 11.41% from -$9.7 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Net Income towards Common Stockholders high stood at $4,899 for Q1 2023, and its period low was -$45.2 million during Q4 2022.
  • In the last 3 years, Insight Molecular Diagnostics' Net Income towards Common Stockholders had a median value of -$9.3 million in 2024 and averaged -$10.9 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 100.05% in 2023, then plummeted by 190,649.09% in 2024.
  • Insight Molecular Diagnostics' Net Income towards Common Stockholders (Quarterly) stood at -$35.9 million in 2021, then declined by 25.97% to -$45.2 million in 2022, then soared by 64.21% to -$16.2 million in 2023, then crashed by 107.84% to -$33.6 million in 2024, then rose by 19.56% to -$10.9 million in 2025.
  • Its Net Income towards Common Stockholders was -$10.9 million in Q3 2025, compared to -$9.7 million in Q2 2025 and -$6.7 million in Q1 2025.